Evercore ISI raised the firm’s price target on BioCryst (BCRX) to $12 from $10 and keeps an Outperform rating on the shares. The company preannounced 2024 Orladeyo revenue of $437M, $2M ahead of the upper end of the guidance range and beating consensus by $4M, notes the analyst, who thinks 2025 guidance of $515-$535M for Orladeyo revenue is “conservative” when considering the 5% price increase and availability of funds to cover Medicare copay this year.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCRX: